Beckman Coulter Diagnostics appoints Catherine Jennings as President to lead global diagnostics growth and innovation
20 Oct 2026
Catherine ‘Cat’ Jennings, President, Beckman Coulter Diagnostics
Summary: Beckman Coulter Diagnostics, a Danaher company, has appointed Catherine ‘Cat’ Jennings as President. The former Boston Scientific Vascular Therapies President will lead the company’s strategic, operational and organizational priorities, with a focus on accelerating diagnostic innovation, strengthening global impact and helping laboratories and clinicians improve patient outcomes.
Beckman Coulter Diagnostics, a Danaher company and a global leader in clinical diagnostics, today announced the appointment of Catherine ‘Cat’ Jennings as President. In this role, Jennings will lead the company’s strategic, operational and organizational priorities, applying a culture of continuous improvement to accelerate innovation, strengthen global impact and help laboratories and clinicians deliver better patient outcomes.
Jennings brings more than 20 years of healthcare industry leadership experience and a proven track record of driving growth, innovation and transformation across global healthcare organizations.
She joins Beckman Coulter Diagnostics from Boston Scientific, where she most recently served as President of Vascular Therapies, leading a global business of approximately $2 billion in annual revenue.
“Cat is an accomplished healthcare leader with a strong track record of driving growth, fostering innovation and developing high-performing teams,” said Kevin O’Reilly, Group Executive, Danaher Diagnostics.
“As part of Danaher’s connected diagnostics ecosystem, Beckman Coulter Diagnostics brings together deep expertise, global scale and customer partnership to address some of healthcare’s toughest challenges. Cat’s leadership will help us accelerate innovation and expand the impact of diagnostic solutions around the world.”
“It is an honour to join Beckman Coulter Diagnostics, a company with a remarkable legacy of innovation and a mission deeply aligned with my passion for improving patient outcomes,” said Jennings. “Diagnostics play a critical role in helping clinicians make informed decisions. I look forward to collaborating closely with customers, healthcare providers and partners around the world to solve some of the most demanding problems in diagnostics and help bring meaningful innovation to patients faster.”
Jennings earned a Bachelor of Science in Biology from Georgetown University and a Master of Business Administration from the University of California, Los Angeles.
As President, Jennings will build on Beckman Coulter Diagnostics' strong foundation, global scale and commitment to advancing healthcare through diagnostics. Around the world, more than one million tests per hour are run on Beckman Coulter Diagnostics laboratory systems, impacting approximately 1.2 billion patients and more than three million clinicians annually.
Cat will lead the company as it continues to expand diagnostic insights that help laboratories, healthcare providers and health systems deliver better patient outcomes.
Want the latest science news straight to your inbox? Become a SelectScience member for free today>>
Links
Tags
Frequently asked questions
Show frequently asked questions
Who is the new President of Beckman Coulter Diagnostics?
Catherine ‘Cat’ Jennings has been appointed President of Beckman Coulter Diagnostics, a Danaher company and global clinical diagnostics business.
What will Catherine Jennings be responsible for?
Jennings will lead Beckman Coulter Diagnostics’ strategic, operational and organisational priorities. Her remit includes accelerating innovation, strengthening the company’s global impact and supporting laboratories and clinicians in improving patient outcomes.
What experience does Catherine Jennings bring to the role?
Jennings has more than 20 years of healthcare industry leadership experience. She joins from Boston Scientific, where she most recently served as President of Vascular Therapies and led a global business generating approximately $2 billion in annual revenue.
What is Catherine Jennings’ educational background?
Jennings holds a Bachelor of Science in Biology from Georgetown University and a Master of Business Administration from the University of California, Los Angeles.
How widely are Beckman Coulter Diagnostics systems used?
More than one million tests per hour are run on Beckman Coulter Diagnostics laboratory systems worldwide, affecting approximately 1.2 billion patients and more than three million clinicians each year.
What will Beckman Coulter Diagnostics focus on under Jennings’ leadership?
The company will continue expanding diagnostic insights and advancing healthcare through diagnostics, while using its global scale, customer partnerships and place within Danaher’s connected diagnostics ecosystem to address complex healthcare challenges.